Candida auris is an emerging fungus that is multi-drug resistant. The CDC has classified Candida auris as a rapidly emerging fungus that has been the cause of tens of thousands of outbreaks in the healthcare setting, including ear, wound and bloodstream infections. This species of Candida is difficult to identify through conventional laboratory methods and its transmission is not completely understood, which poses the question; Are healthcare workers identifying and treating this rapidly spreading fungus properly?
The CDC has collaborated with the FDA to provide a bank of Candida auris isolates to be used to challenge devices and antimicrobial/anti-fungal agents. BioScience Laboratories has acquired this collection of isolates to help our clients test their products against this emerging fungus. BSLI can help customize a study using a Time Kill assay, MIC/MBC assay, or a hard surface disinfectant test for your product against Candida auris.
BSLI is a Service-Disabled Veteran-Owned Small Business
February 27, 2018
Are You Ready to Start Your Next Preservative Efficacy Test?
November 27, 2017
Expanded Biofilm Services
June 14, 2017
What Equivalence Means
April 26, 2017
Statistics, or How to Meet FDA Requirements
April 26, 2017
BioScience Laboratories, Inc. Biofilm Testing Capabilities
February 08, 2017
ISO 17025 ACCREDITATION
August 16, 2016
Anti-Biofilm Technologies: Pathways to Product Development
April 04, 2016
Russell Griggs, M.S., Presents Poster at AORN 2016
March 29, 2016
Neutralizing Your Product(s)
February 01, 2016
Materials Testing: Are You Stressed Out?
November 19, 2015
New Dedicated Materials Testing Lab
August 20, 2015